Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | PPARG | P37231 | 4/20 | 0.51 |
| ▸ | PPARA | Q07869 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.46 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9818914 | 1.00 | CYP1A2 (0.65) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL9819072 | 1.00 | CYP1A2 (0.65) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL11154253 | 0.94 | CYP1A2 (0.59) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL4262556 | 0.89 | CYP1A2 (0.77) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL11511086 | 0.86 | NR4A2 (0.61) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL6617425 | 0.84 | ALDH1A1 (0.64) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL11550164 | 0.83 | CYP1A2 (0.69) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL8900988 | 0.83 | CYP1A2 (0.69) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL23368023 | 0.82 | ALDH1A1 (0.53) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL11209577 | 0.82 | ALDH1A1 (0.62) | CYP1A2GAACYP2C9PKMCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2023-08-22 | — | — | US | disclosed |
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2023-08-22 | — | — | US | disclosed |
| CN-110156813-B | Heterocyclic compounds as TRK inhibitors | 北京诺诚健华医药科技有限公司 | 2023-07-25 | — | — | CN | disclosed |
| US-20220409566-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-12-29 | — | — | US | disclosed |
| US-20220142961-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-05-12 | — | — | US | disclosed |
| US-11318111-B2 | CCL5 inhibitors | LAPKO INC (US) | 2022-05-03 | — | — | US | disclosed |
| US-11299745-B1 | Herbicide resistance genes | DOW AGROSCIENCES LLC (US) | 2022-04-12 | — | — | US | disclosed |
| US-20220098610-A1 | NOVEL HERBICIDE RESISTANCE GENES | DOW AGROSCIENCES LLC (US) | 2022-03-31 | — | — | US | disclosed |
| US-11147788-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2021-10-19 | — | — | US | disclosed |
| US-20210196665-A1 | CCL5 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-4155905-A | 6-Substituted penicillanic acid and derivatives thereof | E. R. SQUIBB & SONS, INC. (US) | 1979-05-22 | — | — | US | disclosed |
| US-4125732-A | HYPOLIPIDEMIC | AMERICAN CYANAMID COMPANY (US) | 1978-11-14 | — | — | US | disclosed |
| US-4119487-A | FROM 3-CHLORO-2-SULFOPROPIONIC ACID | NATIONAL STARCH & CHEMICAL CORPORATION (US) | 1978-10-10 | — | — | US | disclosed |
| US-4077967-A | 6-Substituted penicillanic acid and derivatives thereof | E. R. SQUIBB & SONS, INC. (US) | 1978-03-07 | — | — | US | disclosed |
| US-4061851-A | 7-Amino-7-arylthio cephalosporins | E. R. SQUIBB & SONS, INC. (US) | 1977-12-06 | — | — | US | disclosed |
| US-4061629-A | 6-Amino-6-arylthio penicillanic acids and derivatives thereof | E. R. SQUIBB & SONS, INC. (US) | 1977-12-06 | — | — | US | disclosed |
| US-4029669-A | 6-Benzalimino-6-arylthio penicillanic acids and derivatives thereof | E. R. SQUIBB & SONS, INC. (US) | 1977-06-14 | — | — | US | disclosed |
| US-4026886-A | 7-Acyl-7-arylthiocephalosporins | E. R. SQUIBB & SONS, INC. (US) | 1977-05-31 | — | — | US | disclosed |
| US-3965093-A | 6-Arylthio penicillanic acid and derivatives thereof | E. R. SQUIBB & SONS, INC. (US) | 1976-06-22 | — | — | US | disclosed |
| US-3954744-A | ANTIBACTERIAL | E. R. SQUIBB & SONS, INC. (US) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142961-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | CYP1A2 2919/4885GAA 2392/4885CYP2C9 1183/4885 |
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, RYR2 | CYP1A2 4681/4885GAA 2463/4885CYP2C9 4788/4885 |
| US-11147788-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, RYR2 | CYP1A2 4681/4885GAA 2463/4885CYP2C9 4788/4885 |
| US-20210196665-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | CYP1A2 2919/4885GAA 2392/4885CYP2C9 1183/4885 |
| US-11318111-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | CYP1A2 2919/4885GAA 2392/4885CYP2C9 1183/4885 |
| US-20220409566-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | CYP1A2 2919/4885GAA 2392/4885CYP2C9 1183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.